VITRAKVI® (LAROTRECTINIB)

Updated Vitrakvi® (larotrectinib) Sub-Analysis at ATA 2021 Supports Efficacy and Safety in Adult and Pediatric TRK Fusion Thyroid Cancer Patients

Retrieved on: 
Monday, October 4, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Vitrakvi® (larotrectinib), TRK Fusion Cancer, Oncology at Bayer, Bayer, VITRAKVI® (LAROTRECTINIB), TRK FUSION CANCER, ONCOLOGY AT BAYER, BAYER

Updated thyroid sub-analysis of 29 adult and pediatric TRK fusion cancer patients, of which 28 were evaluable, treated with Vitrakvi (larotrectinib) showed notable overall response rates (ORR) and duration of response (DoR).

Key Points: 
  • Updated thyroid sub-analysis of 29 adult and pediatric TRK fusion cancer patients, of which 28 were evaluable, treated with Vitrakvi (larotrectinib) showed notable overall response rates (ORR) and duration of response (DoR).
  • These data in patients with thyroid cancer further underscore the importance of integrating biomarker-driven oncology medicines into cancer care, so that appropriate patients can potentially benefit from a targeted treatment approach.
  • TRK fusion cancer occurs when an NTRK gene fuses with another unrelated gene, producing a chimeric TRK protein.
  • These TRK fusion proteins are oncogenic drivers promoting cell growth and survival, leading to TRK fusion cancer.

Latest Analyses of Vitrakvi® (larotrectinib) Support Consistently Meaningful Clinical Profile for Both Adult and Pediatric Patients with TRK Fusion Cancer

Retrieved on: 
Thursday, September 16, 2021
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Vitrakvi® (larotrectinib), TRK Fusion Cancer, Oncology at Bayer, Bayer, VITRAKVI® (LAROTRECTINIB), TRK FUSION CANCER, ONCOLOGY AT BAYER, BAYER

The long-term data for Vitrakvi continue to support consistent responses and similar safety profile seen with the addition of new patients and with longer follow-up.

Key Points: 
  • The long-term data for Vitrakvi continue to support consistent responses and similar safety profile seen with the addition of new patients and with longer follow-up.
  • In patients who received Vitrakvi following one line of systemic therapy (n=59), the ORR was 73% (95% CI 6084).
  • TRK fusion cancer occurs when an NTRK gene fuses with another unrelated gene, producing a chimeric TRK protein.
  • These TRK fusion proteins are oncogenic drivers promoting cell growth and survival, leading to TRK fusion cancer.

Bayer to Highlight Expanded Research from Growing Oncology Portfolio at ESMO Congress 2021

Retrieved on: 
Thursday, September 9, 2021
Science, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Other Health, Vitrakvi® (larotrectinib), NUBEQA® (darolutamide), Xofigo® (radium Ra 223 dichloride) Injection, Aliqopa® (copanlisib) Injection, Stivarga® (regorafenib), Oncology at Bayer, Bayer, VITRAKVI® (LAROTRECTINIB), NUBEQA® (DAROLUTAMIDE), XOFIGO® (RADIUM RA 223 DICHLORIDE) INJECTION, ALIQOPA® (COPANLISIB) INJECTION, STIVARGA® (REGORAFENIB), ONCOLOGY AT BAYER, BAYER

Bayer will present new investigational data from its established portfolio of approved oncology therapies at the upcoming ESMO Congress 2021 from September 16-21, 2021.

Key Points: 
  • Bayer will present new investigational data from its established portfolio of approved oncology therapies at the upcoming ESMO Congress 2021 from September 16-21, 2021.
  • The oncology franchise at Bayer includes six marketed products and several other assets in various stages of clinical development.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.
  • BAYER, the Bayer Cross, Vitrakvi, NUBEQA, Xofigo, Aliqopa and Stivarga are registered trademarks of Bayer.

Long-term Data on Vitrakvi® (larotrectinib) Further Demonstrate Strong Clinical Profile in Patients with TRK Fusion Cancer Regardless of Tumor Type and Age

Retrieved on: 
Wednesday, May 19, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Fitness & Nutrition, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, Health sciences, Health, Tyrosine kinase receptors, Orphan drugs, Clinical medicine, Larotrectinib, Cancer, Clinical trial, Trk receptor, Vitrakvi® (larotrectinib), TRK Fusion Cancer, Oncology at Bayer, Bayer, VITRAKVI® (LAROTRECTINIB), TRK FUSION CANCER, ONCOLOGY AT BAYER, BAYER

In addition, an intra-patient pooled retrospective analysis assessing the treatment effect of Vitrakvi in patients with TRK fusion cancer previously treated with one or more line of therapy were presented.

Key Points: 
  • In addition, an intra-patient pooled retrospective analysis assessing the treatment effect of Vitrakvi in patients with TRK fusion cancer previously treated with one or more line of therapy were presented.
  • Two percent of patients discontinued Vitrakvi due to TRAEs and no treatment-related deaths were reported.\nData for the integrated dataset were pooled from three Vitrakvi clinical trials (NCT02122913, NCT02576431 and NCT02637687) in adult and pediatric patients with TRK fusion cancer.
  • These TRK fusion proteins are oncogenic drivers promoting cell growth and survival, leading to TRK fusion cancer.
  • Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer \xe2\x80\x93 an expanded dataset [abstract].

Bayer Presents Latest Data and New Research to Advance Cancer Care within Oncology Portfolio at 2021 ASCO Annual Meeting 

Retrieved on: 
Tuesday, May 11, 2021
Research, Other Health, General Health, Oncology, Genetics, Fitness & Nutrition, Clinical trials, Science, Cardiology, Biotechnology, FDA, Health, Other Science, Branches of biology, Companies, Life sciences, Aspirin, Bayer, IG Farben, Leverkusen, Asco, American Society of Clinical Oncology, Larotrectinib, Fetus, Vitrakvi® (larotrectinib), NUBEQA® (darolutamide), Xofigo® (radium Ra 223 dichloride) Injection, Aliqopa® (copanlisib) Injection, Stivarga® (regorafenib), NEXAVAR® (sorafenib) Tablets7, Oncology at Bayer, Bayer, VITRAKVI® (LAROTRECTINIB), NUBEQA® (DAROLUTAMIDE), XOFIGO® (RADIUM RA 223 DICHLORIDE) INJECTION, ALIQOPA® (COPANLISIB) INJECTION, STIVARGA® (REGORAFENIB), NEXAVAR® (SORAFENIB) TABLETS7, ONCOLOGY AT BAYER, BAYER

b'Bayer will present new data across its oncology portfolio at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021.

Key Points: 
  • b'Bayer will present new data across its oncology portfolio at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021.
  • If withheld, modify the VITRAKVI dosage when resumed.\nEmbryo-Fetal Toxicity: VITRAKVI can cause fetal harm when administered to a pregnant woman.
  • The oncology franchise at Bayer includes six marketed products and several other assets in various stages of clinical development.
  • These factors include those discussed in Bayer\xe2\x80\x99s public reports which are available on the Bayer website at www.bayer.com .